Contract for procurement of Mogamulizumab 20 mg in 5mL concentrate for solution for infusion
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Region | Northern Ireland |
| Procedure | limited |
| OCID | ocds-h6vhtk-03f7ea |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| ALLOGA UK LTD | · | · | active |
description
Contract for procurement of Mogamulizumab 20 mg in 5mL concentrate for solution for infusion for three years
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 30 Aug 2023 | Contract award notice (F03) | Earlier regulations | 025423-2023 |
more from Northern Health and Social Care Trust
- Early Market Engagement - Learning Disability Supported Living Accommodation in the preferred areas of Larne/Carrickfergus or Antrim/Ballymena areas as secondary options · 23 Jul 2026
- Early Market Engagement - Learning Disability Supported Living Accommodation in the preferred areas of Ballymena and Causeway, but the Trust will consider other areas as secondary options. · 22 Jun 2026
- Early Market Engagement – Learning Disability Supported Living Accommodation in the preferred area of Newtownabbey, but the Trust will consider other areas as secondary options. · 8 Apr 2026
- Information for consent forms · 5 Nov 2025
- Early Market Engagement - Learning Disability Supported Living Accommodation in the preferred area of Ballymoney, but the Trust will consider other areas as secondary options. · 1 Oct 2025
- Early Market Engagement - Learning Disability Supported Living Accommodation within any area of Northern Ireland. · 1 Oct 2025
- Early Market Engagement - Learning Disability Supported Living Accommodation in the preferred areas of Causeway and Ballymena but the Trust will consider other a · 21 Aug 2025
- Early Market Engagement - Learning Disability Supported Living Accommodation in the preferred areas of Causeway, Ballymena and Antrim areas but the Trust will consider other areas as secondary options. · 1 Jul 2025
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.